Key Takeaways Novavax reported strong immune responses from its COVID-19-influenza combo in adults 65 and older. The study guides the design for another late-stage trial that could support regulatory submissions. Novavax seeks partnerships to fund the development and commercialization of both vaccine candidates.Novavax (NVAX) announced encouraging results from an initial cohort of a late-stage study evaluating its experimental COVID-19-influenza combination (CIC) and stand-alone influenza vaccine candidat ...